Invega Sustenna (Paliperidone Palmitate) Patent Expiration, LOE Window & CMS Spending
Invega Sustenna (Paliperidone Palmitate) by Johnson & Johnson: FDA Orange Book LOE 2031-01-26, 11 AB generics, $3.64B 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N022264 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-01-26 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 11 |
| 2024 CMS Total Public Spend | $3.64B |
| 2024 Medicare Part D Spend | $1.88B |
| 2024 Medicaid Spend | $1.76B |
| Reported Wholesale Price Change (CA SB 17) | 10 WAC filings (max 19.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.